{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Wikipedia|List of designer drugs|Androgens|DHT based" in comments (approximate match)
Status:
Investigational
Source:
NCT00095212: Not Applicable Interventional Completed HIV Infection
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Methyl-1-testosterone(M1T)(17alpha-hydroxy-17-methyl-
5-androst-1-en-3-one) is a new designer steroid that is most likely produced to circumvent
the legal restrictions. It is advertised to be highly
anabolic and moderately androgenic and not convertible
to estrogens. However, in scientific literature, it was reported
to show anabolic properties of 25% and androgenic
properties of 50% compared with testosterone propionate
after im injection in castrated rats. In February
2006, Health Canada (Federal Department) warned consumers
not to use M1T-containing products because of
potentially serious health risks such as liver disorders and
hardening of the arteries. Since 2006, M1T is explicitly listed on the
World Anti-Doping Agency list of prohibited substances,
and therefore, its use by athletes is prohibited.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
The 17-ketosteroid epiandrosterone is a metabolite of testosterone precursor dehydroepiandrosterone (DHEA).
Epiandrosterone have been considered to be merely inactive end product of DHEA, but may in fact be physiological effectors in their own right. It is formed in peripheral tissues, from which it is released into the circulation and is ultimately excreted in the urine. Epiandrosterone is only a weak androgen, but it is widely recognized to inhibit the pentose phosphate pathway and to decrease intracellular NADPH levels. Epiandrosterone may act as a L-type Ca2+ channel antagonist. Epiandrosterone mainly transformed into 17beta-hydroxylated derivatives, 7- or 16alpha-hydroxylated metabolites under NAD(P)H conditions, and 5alpha-androstane-3,17-dione under NAD(P)+ conditions. Epiandrosterone is used as an anabolic agent (dietary supplement, a precursor to dihydrotestosterone) to increase strength, muscle hardness and also improves libido.
Status:
US Previously Marketed
Source:
OXANDROLONE by SANDOZ
(2006)
Source URL:
First approved in 1964
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Oxandrolone is a synthetic, orally active anabolic-androgenic steroid. Oxandrolones interact with androgen receptors in target tissues. Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Side effects include: elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations). Cardiovascular side effects have included edema, with and without congestive heart failure. Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
Status:
US Previously Marketed
Source:
WINSTROL by LUNDBECK INC
(1962)
Source URL:
First approved in 1962
Source:
WINSTROL by LUNDBECK INC
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Stanozolol is a synthetic anabolic steroid derived from dihydrotestosterone. It is indicated prophylactically to decrease the frequency and severity of attacks of angioedema. In rare cases, serious and even fatal cases of liver problems have developed during treatment with stanozolol. Anabolic steroids may increase sensitivity to anticoagulants; therefore, dosage of an anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level.
Status:
US Previously Marketed
Source:
DROLBAN by LILLY
(1961)
Source URL:
First approved in 1961
Source:
DROLBAN by LILLY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Dromostanolone Propionate (known by the brand names Masteron and Drolban) was invented by Syntex in 1959. About 10 years later it was released on the American market by Lilly as brand name Drolban. The drug was first approved in the USA for use as a treatment of female breast cancer. However, the profile of side-effects included pronouncement of male characteristics in women and when more effective breast cancer treatments came to market drostanolone was gradually phased out. No longer used clinically dromostanolone propionate became very popular in the bodybuilding community. Today dromostanolone propionate remains on the list of approved medications, but it is not being manufactured or sold by pharmaceutical companies. It is still produced illegally by underground labs for use in the bodybuilding community.
Status:
First approved in 1953
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
STANOLONE, also known as dihydrotestosterone, is a potent androgenic metabolite of testosterone and anabolic agent for systemic use. It may be used as a replacement of male sex steroids in men who have androgen deficiency, for example as a result of the loss of both testes, and also the treatment of certain rare forms of aplastic anemia which are or may be responsive to anabolic androgens.